Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion type Assertion NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_head.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion description "[Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion evidence source_evidence_literature NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion SIO_000772 23846442 NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion wasDerivedFrom befree-20150227 NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.
- NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_assertion wasGeneratedBy ECO_0000203 NP519289.RA3ioWVPqOcIyYv4VQjrBiWTvEi0fTlpfFOX9S6xO1RKA130_provenance.